SEC Form 4 <b>FO</b>	RM 4	UNITED S	TATES SECURITIES AND EXCHANGE CON Washington, D.C. 20549	MISSION	
Section 16. Fo	t if no longer subject to rm 4 or Form 5 y continue. <i>See</i> ).	STATE	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	ERSHIP	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
BOESS CA (Last) C/O KINIKSA	ress of Reporting Pe <u>RSTEN</u> (First) A PHARMACEUT N HOUSE 2 CHU	(Middle) TICALS, LTD.	2. Issuer Name and Ticker or Trading Symbol <u>Kiniksa Pharmaceuticals, Ltd.</u> [ KNSA ] 3. Date of Earliest Transaction (Month/Day/Year) 05/29/2018	5. Relationship of R (Check all applicabl Director Officer (giv below)	X 10% Owner
(Street) HAMILTON (City)	D0 (State)	HM11 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	X Form filed	t/Group Filing (Check Applicable Line) by One Reporting Person by More than One Reporting Person

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Class A Common Shares	05/29/2018		С		6,392	Α	\$0.00	79,589	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numbe Derivativ Securitie Acquired Disposed (Instr. 3,	e s I (A) or I of (D)	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and of Securiti Underlying Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Preferred Shares	(1)	02/09/2018		Р		6,392 <sup>(2)</sup>		(1)	(1)	Class A Common Shares	6,392 <sup>(2)</sup>	\$15.6438 <sup>(2)</sup>	6,392 <sup>(2)</sup>	D	
Series A Preferred Shares	(3)	05/29/2018		С			107,050	(3)	(3)	Class B Common Shares	107,050	\$0.00	0	D	
Series C Preferred Shares	(1)	05/29/2018		С			6,392	(1)	(1)	Class A Common Shares	6,392	\$0.00	0	D	
Class B Common Shares	(4)	05/29/2018		С		107,050		(4)	(4)	Class A Common Shares	107,050	\$0.00	473,035	D	

Explanation of Responses:

1. Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis.

2. Reflects the 1-for-2.73235 share consolidation effected May 11, 2018.

3. Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis.

4. Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party.

<u>/s/ Thomas W. Beetham,</u>
Attorney-in-Fact for Carsten
Boess
** Signature of Reporting Person

05/29/2018

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.